Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immutep Ltd ADR (NQ: IMMP )

1.770 -0.030 (-1.67%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55,010
Open 1.770
Bid (Size) 1.720 (15)
Ask (Size) 1.870 (1)
Prev. Close 1.800
Today's Range 1.760 - 1.770
52wk Range 1.470 - 3.390
Shares Outstanding 748,152,935
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Did Immutep Ltd Stock Soar Recently?
Analysts and investors alike appear enamored with Immutep Ltd, whose earnings are growing; more of which could come from their latest product candidate. 
Via MarketBeat
Topics Initial Public Offering
Exposures Product Safety Securities Market
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
From Immutep Limited
Via Globe NewsWire

Performance

YTD
-3.28%
-3.28%
1 Month
+1.14%
+1.14%
3 Month
-11.50%
-11.50%
6 Month
+3.51%
+3.51%
1 Year
-43.09%
-43.09%

More News

Read More
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
From Immutep Limited
Via Globe NewsWire
Immutep Issues Development Update For Its Lead Cancer Candidate
Via Benzinga
Why Are Immutep Shares Trading Higher?
Via Benzinga
Why AeroClean Technologies Is Trading Higher By Over 39%; Here Are 26 Stocks Moving Premarket
Via Benzinga
Immutep's Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Via Benzinga
FDA Backs Immutep's Eftilagimod Registrational Trial In Metastatic Breast Cancer
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
75 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
58 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Immutep's Lead Candidate Data In Breast Cancer Trial Fails To Lift The Stock
Via Benzinga
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Via Benzinga
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.